Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The CFO departed effective April 15, 2026, as determined by the Board with no disclosed reason.
Tango Therapeutics CFO Daniella Beckman departs with generous severance package
Filed May 8, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
CFO Daniella Beckman separated effective April 15, 2026, as determined by the Board. Her last day of employment was May 1, 2026. No reason for departure was disclosed in the filing.
Item 5.02 verify on EDGAR → -
medium
Beckman receives 12 months base salary severance paid over 12 months, plus 12 months of COBRA health insurance premium reimbursement under the separation agreement dated May 7, 2026.
Item 5.02 verify on EDGAR → -
medium
Company accelerated vesting on Beckman's stock options and restricted stock units equivalent to 24 months of additional service beyond her May 1 departure date, potentially diluting existing shareholders.
Item 5.02 verify on EDGAR → -
low
Beckman's vested stock options can be exercised through August 31, 2026, extending the typical post-termination exercise window by several months.
Item 5.02 verify on EDGAR →
Summary
Tango Therapeutics announced that CFO Daniella Beckman separated from the company effective April 15, 2026, with her last day of employment on May 1, 2026. The Board determined the separation on April 10, but the 8-K provides no explanation for the departure—whether voluntary, performance-related, or part of a restructuring.
The lack of disclosure raises questions investors should monitor in upcoming earnings calls or filings. The separation package is notably generous. Beyond standard 12-month severance and COBRA benefits, Beckman receives 24 months of accelerated equity vesting—meaning options and restricted stock units that wouldn't have vested until May 2028 now vest immediately.
This represents significant additional compensation and potential shareholder dilution. For a biotech company like Tango, CFO stability matters as the firm navigates clinical trials and capital allocation decisions. Investors should watch for: (1) announcement of a permanent CFO replacement and their background, (2) any MD&A discussion in the next 10-Q about financial strategy changes, and (3) whether insider selling activity increases following Beckman's extended option exercise period through August 31.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
CFO Daniella Beckman separated; receives 12 months severance, COBRA, 24 months accelerated vesting, and extended option exercise period.
Added in current filing · verify on EDGAR →
on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.
The Board determined that Daniella Beckman would no longer serve as CFO, principal accounting officer, and principal financial officer effective April 15, 2026. This represents a leadership change in the company's financial management.
Added in current filing · verify on EDGAR →
on May 7, 2026, the Company and Ms. Beckman entered into a Separation Agreement and Release (the “Separation Agreement”). Pursuant to the terms of the Separation Agreement and to the terms of that certain Employment Agreement by and between the Company and Ms. Beckman, the Company has agreed to provide certain benefits to Ms. Beckman, including the following: (i) twelve months of severance pay at Ms. Beckman’s current base salary, paid out in substantially equal installments over 12 months and (ii) reimbursement for any monthly COBRA premium payments for up to 12 months.
The company entered into a separation agreement with Ms. Beckman providing 12 months of severance pay at her current base salary and 12 months of COBRA premium reimbursement. These are standard separation benefits for an executive departure.
Added in current filing · verify on EDGAR →
The Company also agreed to accelerate the vesting of such number of Ms. Beckman’s outstanding option and restricted stock unit awards that would have otherwise vested had Ms. Beckman remained in continuation of her service with the Company for an additional twenty-four months following May 1, 2026, Ms. Beckman’s last day of employment with the Company.
The company accelerated vesting of Ms. Beckman's equity awards equivalent to 24 months of additional service beyond her May 1, 2026 last day of employment. This represents significant additional compensation beyond standard severance and may dilute existing shareholders.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In addition, the Company agreed to extend the post-termination exercise period for any of Ms. Beckman’s vested stock options as of the date of the Separation Agreement through August 31, 2026.
The company extended the exercise period for Ms. Beckman's vested stock options through August 31, 2026, giving her additional time beyond standard post-termination exercise windows to exercise her options.
Event · Item 9.01 — Financial Statements and Exhibits
Tango Therapeutics disclosed a separation agreement with Daniella Beckman effective May 7, 2026.
Added in current filing · verify on EDGAR →
Separation Agreement, dated as of May 7, 2026 by and between the Company and Daniella Beckman.
The company entered into a separation agreement with Daniella Beckman on May 7, 2026. The 8-K does not specify Beckman's role or the terms of the separation, but the filing of a separation agreement typically indicates the departure of an executive or key employee. Investors should review the full exhibit for details on severance payments, equity treatment, and any restrictive covenants.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify